News

Intercell in €25m finance deal with BB Biotech
Enlarge image

BusinessAustriaSwitzerland

Intercell in €25m finance deal with BB Biotech

09.05.2012 - Austrian biotech company Intercell AG has signed a €25m financing deal with Swiss investor BB BiotechAG.

Vienna  – The vaccine maker also said it is in talks with other investors   concerning a private stock placement that could total €15m. The  investment, through a fully owned subsidiary of BB Biotech AG, consists of a €20m secured loan and a commitment to invest €5m as part  of a proposed private share placement. Intercell’s CEO, Thomas Lingelbach, stated: “Following the successful strategic resetting in  2011, this financing marks an important step in the renewal of  Intercell as a notable biotech vaccine company. With growing sales  from our first product on the market, a diversified pipeline and  technology base and a disciplined financial strategy, we are now very  well positioned for the next development phase of our company.”

Intercell is trying to get back on track after several product setbacks sparked worries about its pipeline prospects. After a setback  in the development of a traveller’s diarrhoea vaccine last year, the  new focus of the company is on vaccines preventing nosocomial  infections. The secured six-year loan carries a variable interest  rate. Intercell will pay BB Biotech royalties on sales revenues from  its product Ixiaro, a vaccine for Japanese encephalitis. The €5m  equity investment will see BB Biotech subscribe for nearly 2 million  Intercell shares for about 2.55 € per share as part of the private  placement. According to Intercell,  existing shareholders will not get  subscription rights for the placement

http://www.european-biotechnology-news.com/news/news/2012-02/intercell-in-eur25m-finance-deal-with-bb-biotech.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR29.5%
  • ADDEX3.30 CHF6.5%
  • BB BIOTECH150.50 EUR2.6%

FLOP

  • CYTOS0.16 CHF-33.3%
  • 4SC0.80 EUR-31.6%
  • PAION2.20 EUR-27.9%

TOP

  • SANTHERA81.90 CHF2072.4%
  • CO.DON2.69 EUR174.5%
  • PAION2.20 EUR144.4%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014